Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir)
Internal Medicine Journal
John Wiley and Sons, Inc
School of Medical and Health Sciences
A 55‐year‐old previously well man diagnosed with stage IIIB melanoma in 2016, developed disease progression with lung, left adrenal and perinephric soft tissue metastases while on an adjuvant pembrolizumab/placebo phase III study. Pembrolizumab is a programmed death 1 (PD‐1) receptor blocking antibody1 that is currently used in the treatment of metastatic melanoma. On unblinding, he was on the placebo arm, and was subsequently commenced on three weekly pembrolizumab monotherapy. Following four cycles of immunotherapy, an early response was seen in his lung and perinephric soft tissue metastases. On further assessment for his suitability for another phase 1 study, he was found to be hepatitis C antibody and polymerase chain reaction positive with a rising alanine transaminase, since the commencement of pembrolizumab.